Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Waldenström Macroglobulinemia
Related studies linked through entity extraction aliases.
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- NA
Ipilimumab and Local Radiation for Selected Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE2
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE1
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE2
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE2
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- NA
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2